Credit: Michigan State University Michigan State University scientists are testing a promising drug that may stop a gene associated with obesity from triggering breast and lung cancer, as well as prevent these cancers from growing. These findings are based on two studies featured in the latest issue of Cancer Prevention Research. The first was a...
Tag: <span>Lung cancer</span>
Post
RNA-based therapeutic inhibits a metabolic pathway in tumor-initiating lung cancer cells
RNA-based therapeutics that prevent a key metabolic enzyme from being expressed in tumor-initiating cells (TIC) hold promise for the treatment of lung cancer, an A*STAR team has shown. As implied by their name, TIC – also known as cancer stem cells – are a subset of tumor cells with the capacity to self-renew and start new tumors. Abnormal metabolism is...
Post
Encouraging oxygen’s assault on iron may offer new way to kill lung cancer cells
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published online November 22 in Nature. Human cells contain...
Post
Lung cancer triggers pulmonary hypertension
Hypertension associated with lung cancer: In the diagram, a tumour is shown in the right lung. Histological comparison of two blood vessels shows dramatic thickening of the wall of the vessel removed from the tumour region. Changes in blood …more Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients....
Post
Tarloxitinib puts tumor-seeking tail on anti-EGFR drug to precisely target lung cancer
EGFR is a common genetic target in lung cancer, but not all EGFR mutations are created equal. Patients with a type of EGFR anomaly called an “EGFR exon 20 insertion” often fail to respond to existing drugs targeting EGFR. Previous work shows this is because it simply takes a much higher concentration of anti-EGFR drugs...
Post
Lung cancer driver ALK-fusion found in melanoma
Melanomas caused by sun exposure have been matched with targeted treatments and immunotherapies, in many cases dramatically extending patients’ lives. However, there are other kinds of melanoma not related to sun exposure and because they are caused by different genetic changes, they are not susceptible to the same targeted treatments. This often leaves patients...
Post
Terry Fox research team’s model for detecting lung cancer saves lives, is a world leader
Vancouver, BC – A pan-Canadian team of cancer researchers has developed a predictive model for detecting early-stage lung cancer in high-risk individuals with significantly greater accuracy than other leading models. This Terry Fox Research Institute study suggests the team’s innovative approach could be considered for use in lung cancer screening programs both in Canada and...
Post
Possible new immune therapy target in lung cancer
Fluorescence microscopy images of blood vessels supported by perivascular cells. The top row shows vessels with perivascular cells from normal lung tissue compared to vessels supported by tumor-derived perivascular cells (bottom row). The …more A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors...
Post
Immunotherapy for lung cancer: What you need to know
Immunotherapy, also known as biologic therapy, may benefit people fighting certain kinds of lung cancer. This treatment option uses medicines to stimulate the body’s immune system so that it can fight the cancer cells more effectively. Immunotherapy has changed the way doctors treat many types of cancer, including lung cancer. In this article, we look at how immunotherapy...
Post
Anti-inflammatory therapy cuts risk of lung cancer
In most clinical trials for cancer therapy, investigators test treatments in patients with advanced disease. But a recent cardiovascular secondary prevention study has given researchers a unique opportunity: to explore the effectiveness of giving a drug to patients before cancer emerges. At the European Society of Cardiology meeting, Paul M. Ridker, MD, director of the...